Search Result

Results for "

anti-amyloid

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (9) Apolipoprotein (1) Beta-secretase (1) Cholinesterase (ChE) (1) EGFR (1) GSK-3 (1) Tau Protein (1)
By Research Areas:	Cancer (1) Inflammation/Immunology (5) Neurological Disease (10)

Inhibitors & Agonists

Inhibitory Antibodies

Targets Recommended: Amyloid-β

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153417

Anti-amyloid agent-1	Amyloid-β	Neurological Disease
Anti-amyloid agent-1 is a potent *anti-amyloid* compound and inhibits amyloid aggregation. Anti-amyloid agent-1, compound ex1140 from patent WO2012119035A1, provides a useful method for amyloidosis treatment research .

HY-P99105

Anselamimab CAEL-101	Apolipoprotein	Neurological Disease
Anselamimab (CAEL-101) a humanized IgG1-κ anti-Amyloid fibrils antibody targeting to *serum amyloid* A1 (SAA1**) .

HY-153430

Aβ/tau aggregation-IN-3	Amyloid-β	Neurological Disease
Aβ/tau aggregation-IN-3 is a potent amyloid protein aggregation inhibitor with an IC₅₀ of 0.85 μM by Aβ-Thioflavin T (Aβ-ThT) functional aggregation assay. Aβ/tau aggregation-IN-3 has anti-amyloid activity .

HY-P9999

Trontinemab RG6102; RO-7126209	Amyloid-β	Neurological Disease
Trontinemab (RG6102) is a brain-penetrant, anti-amyloid, bispecific and humanizedized IgG1-κ antibody, targeting to Aβ plaques and transferrin receptor 1 (TFR1). Trontinemab binds to fibrillar Aβ as well as Aβ plaques triggering plaque clearance by engaging immune cells on Alzheimer disease (AD) brain sections. Trontinemab also shows specific affinity to cynomolgus and human TFR1 .

HY-P99216

Ponezumab 1 Publications Verification PF-04360365; RN 1219	EGFR	Neurological Disease
Ponezumab (PF-04360365) is a humanised anti-amyloid IgG2 monoclonal antibody. Ponezumab reduces Aβ levels in the central nervous system and improves performance in mice in various models of learning and memory. Ponezumab can be used in study of Alzheimer's disease .

HY-169426

Anti-amyloid agent-2	Amyloid-β	Cancer
Anti-amyloid agent-2 (compound (R)-38) is an amyloidogenic immunoglobulin light chain stabilizer .

HY-P991101

Anti-Amyloid Beta Antibody (scFv59)	Amyloid-β	Neurological Disease
Anti-Amyloid Beta Antibody (scFv59) is a human antibody expressed in CHO cells, targeting *Amyloid-β. Anti-Amyloid* Beta Antibody (scFv59) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990332

Anti-Amyloid Beta Antibody (CNTO 2125) CNTO 2125	Amyloid-β	Inflammation/Immunology
Anti-Amyloid Beta Antibody (CNTO 2125) is a humanized antibody expressed in CHO cells, targeting Amyloid Beta/Aβ. Anti-Amyloid Beta Antibody (CNTO 2125) features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-Amyloid Beta Antibody (CNTO 2125) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991046

Donanemab (Mouse IgG2b)	Amyloid-β	Neurological Disease
Donanemab (Mouse IgG2b) is an anti-amyloid inhibitory antibody with Mouse IgG2b. Donanemab can be used in research about Alzheimer's disease .

HY-168079

GSK-3β inhibitor 21	GSK-3 Tau Protein	Neurological Disease Inflammation/Immunology
GSK-3β inhibitor 21 (compound 44) is an ATP-competitive GSK-3β inhibitor (IC₅₀=6.06 μM) with anti-amyloid aggregation and tau phosphorylation inhibitory activities. GSK-3β inhibitor 21 can be used in the study of Alzheimer's disease .

HY-122080

Memoquin	Cholinesterase (ChE) Beta-secretase Amyloid-β	Neurological Disease
Memoquin is an anti-amyloid and anti-oxidant multi-target-directed ligand. Memoquin is an orally active inhibitor of BACE-1 and AChE with IC₅₀ values of 108 and 1.55 nM, respectively. Memoquin is a cognitive enhancer that prevents the Aβ-induced neurotoxicity mediated by oxidative stress. Memoquin can be used for the research of Alzheimer’s disease (AD) .

HY-W265961

Squoxin ST1859; 1,1′-Methylenedi-2-naphthol	Amyloid-β	Neurological Disease Inflammation/Immunology
Squoxin (ST1859) is an antiamyloid agent that specifically binds to Aβ1-42 and prevents the aggregation and fibril formation of Aβ. Squoxin crosses the blood-brain barrier (BBB) and has anthelmintic activity and anti-inflammatory properties .

Cat. No.	Product Name	Target	Research Area

HY-P99105

Anselamimab CAEL-101	Apolipoprotein	Neurological Disease
Anselamimab (CAEL-101) a humanized IgG1-κ anti-Amyloid fibrils antibody targeting to *serum amyloid* A1 (SAA1**) .

HY-P99358

Dezamizumab GSK 2398852; anti-Serum amyloid P/SAP Reference antibody (dezamizumab)	Inhibitory Antibodies	Inflammation/Immunology
Dezamizumab (GSK 2398852) is a fully humanized recombinant monoclonal IgG1 anti-serum amyloid P component (SAP) antibody, with potential anti-amyloid activity. Dezamizumab triggers immunotherapeutic clearance of amyloid. Dezamizumab can be used in research of Amyloid light-chain (AL) amyloidosis .

HY-P9999

Trontinemab RG6102; RO-7126209	Amyloid-β	Neurological Disease
Trontinemab (RG6102) is a brain-penetrant, anti-amyloid, bispecific and humanizedized IgG1-κ antibody, targeting to Aβ plaques and transferrin receptor 1 (TFR1). Trontinemab binds to fibrillar Aβ as well as Aβ plaques triggering plaque clearance by engaging immune cells on Alzheimer disease (AD) brain sections. Trontinemab also shows specific affinity to cynomolgus and human TFR1 .

HY-P99216

Ponezumab 1 Publications Verification PF-04360365; RN 1219	EGFR	Neurological Disease
Ponezumab (PF-04360365) is a humanised anti-amyloid IgG2 monoclonal antibody. Ponezumab reduces Aβ levels in the central nervous system and improves performance in mice in various models of learning and memory. Ponezumab can be used in study of Alzheimer's disease .

HY-P991101

Anti-Amyloid Beta Antibody (scFv59)	Amyloid-β	Neurological Disease
Anti-Amyloid Beta Antibody (scFv59) is a human antibody expressed in CHO cells, targeting *Amyloid-β. Anti-Amyloid* Beta Antibody (scFv59) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990332

Anti-Amyloid Beta Antibody (CNTO 2125) CNTO 2125	Amyloid-β	Inflammation/Immunology
Anti-Amyloid Beta Antibody (CNTO 2125) is a humanized antibody expressed in CHO cells, targeting Amyloid Beta/Aβ. Anti-Amyloid Beta Antibody (CNTO 2125) features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-Amyloid Beta Antibody (CNTO 2125) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990333

Anti-Amyloid Beta Antibody (DLX212) DLX212	Inhibitory Antibodies	Inflammation/Immunology

HY-P991046

Donanemab (Mouse IgG2b)	Amyloid-β	Neurological Disease
Donanemab (Mouse IgG2b) is an anti-amyloid inhibitory antibody with Mouse IgG2b. Donanemab can be used in research about Alzheimer's disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.